Observational Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Apr 26, 2020; 8(8): 1424-1443
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424
Figure 1
Figure 1 Distribution of primary tumour location in colon cancer patients.
Figure 2
Figure 2 Disease recurrence in patients with stage Ι, ΙΙ and ΙΙΙ disease according to RAS mutation status.
Figure 3
Figure 3 Disease recurrence in left colon cancer patients with stage Ι, ΙΙ and ΙΙΙ disease according to RAS mutation status.
Figure 4
Figure 4 Progression-free survival in the first-line chemotherapy setting in patients with initial stage Ι, II and IΙΙ disease according to location.
Figure 5
Figure 5 Progression-free survival in the first-line chemotherapy setting in patients with initial stage IV disease according to RAS mutation status.
Figure 6
Figure 6 Progression-free survival in the first-line chemotherapy setting in patients with final stage IV RAS-wild-type disease receiving panitumumab according to primary tumour location.
Figure 7
Figure 7 Progression-free survival in the first-line chemotherapy setting according to BRAF mutation status.
Figure 8
Figure 8 Overall survival among patients with initial stage I, II and ΙΙΙ disease according to primary tumour location.